12 results about "Disease biomarker" patented technology

The application discloses a preparation method of a VP@UiO-66-NH2 / Ag NPs composite SERS chip and application thereof in A beta protein detection, and is characterized by comprising the following steps: synthesizing a VP-graphite paper base by a chemical vapor transport method on a surface of a graphite paper to obtain a VP-graphite paper base; synthesizing a UiO-66-NH2 layer on the surface of the VP-graphite paper base by a solvothermal method to obtain a VP@UiO-66-NH2 composite base; and finally, placing the composite base in an ion sputtering instrument, uniformly sputtering silver nanoparticles on the surface of the composite base, taking out the composite base, and obtaining the VP@UiO-66-NH2 / Ag NPs composite SERS chip, wherein the VP@UiO-66-NH2 / Ag NPs composite SERS chip has the advantages of high sensitivity, good stability and uniformity, controllable preparation process, low cost, application in Alzheimer's disease biomarker detection, high specificity in identification and quantitative analysis of A beta 40 and A beta 42 proteins, fast response and good stability.

This invention discloses a filter coating composition for fluorescence detection and its preparation method, relating to the fields of optical materials and biodetection technology. The composition is formulated by compounding optical functional powders, polymer substrates, dispersants, and additives in specific proportions, exhibiting high transmittance, narrow wavelength selectivity, excellent weather resistance and mechanical stability. It can accurately filter excitation light and stray light, improving the sensitivity and specificity of fluorescence detection. The filter coating composition and its preparation method for fluorescence detection also provide a simple, cost-effective manufacturing process suitable for large-scale production, particularly applicable to gene sequencing and immunochemistry. It addresses the problems of poor wavelength selectivity, weak stability, and high cost associated with traditional filters, making it suitable for fluorescence detection scenarios such as Alzheimer's disease biomarkers. Balancing accuracy, stability, and economy, it has broad application prospects in the field of in vitro diagnostic reagents.

Systems and methods for detecting a disease biomarker in a subject are provided. In some embodiments, a system includes an oral device configured to be positioned within a subject's mouth, and a hydrogel carried by the oral device, the hydrogel including a polymer and a fluorescent moiety. When the oral device is positioned within the subject's mouth, the hydrogel can be configured to release the fluorescent moiety into the subject's mouth, and the fluorescent moiety can be configured to label a disease biomarker present in the subject's mouth.

Set forth herein are methods useful for identifying disease biomarkers, particularly for diseases such as clear cell renal cell carcinoma (ccRCC). In some examples, the methods set forth herein are useful for monitoring the prognosis of patients having disease such as ccRCC.

The invention discloses a biomarker for diagnosing Alzheimer's disease as well as a screening method and application thereof, relates to the technical field of biomarkers for Alzheimer's disease, and aims to solve the technical problems that the Alzheimer's disease lacks dynamic pathological monitoring indexes and stereoisomeric modification is difficult to systematically detect. According to the invention, the stereoisomeric modification level of peptide fragments KLDLSNVQSK and AKTDHGAEIVYK is used as the core biomarker for the first time, the modification level is remarkably related to the Braak staging of AD, and a detection method and a combined diagnosis model containing the marker are provided. A novel molecular target with high correlation and dynamic monitoring potential is provided for AD, the model diagnosis precision is remarkably improved, and a brand new solution is provided for disease mechanism research and drug development.

This invention provides a sample pretreatment kit and its application for the simultaneous detection of Aβ40, Aβ42, and lencanezumab, belonging to the field of biodetection technology. The kit includes: mixed magnetic beads, internal standard solution, trypsin digestion solution, enzyme digestion enhancer, and ammonia; the mixed magnetic beads are composed of protein A magnetic beads and streptavidin magnetic beads; the internal standard solution is composed of… 15 N-labeled Aβ40, 15 This kit consists of N-labeled Aβ42 and lencanezumab internal standard peptides. The pretreatment kit eliminates the need for anti-IgG1 antibodies, requiring only Protein A for detection, thus shortening sample processing time, greatly simplifying the sample handling process, and increasing throughput. The kit can simultaneously detect Aβ40, Aβ42, and lencanezumab, providing more reliable data support for clinical diagnosis and treatment efficacy evaluation, and significantly promoting the development of companion detection technologies for Alzheimer's disease biomarkers and therapeutic drugs.

This invention belongs to the field of multi-omics data integration technology. It discloses a system for screening multiple disease biomarkers from the gut microbiota metabolome. The system performs batch-to-batch drift correction based on the comparison values ​​of internal reference metabolites on metabolomic mass spectrometry data from multiple disease and healthy control groups. Then, it calculates the covariant stability index between metabolites and microbial species, and constructs a constrained metabolite association network by combining metabolic pathway topological distance. Based on this, the system integrates pathway constraint betweenness centrality and disease effect size to calculate network-enhanced discriminant scores, performs dimensionality reduction according to the principle of maximum coverage and minimum redundancy, and simultaneously evaluates the stability baseline values ​​of biomarker-related ecological functional modules. Finally, using ecological stability as a constraint, the system optimizes the discriminative power of multiple diseases through marginal contribution evaluation, outputting a balanced and efficient biomarker panel. This invention achieves systematic integration of microbiome and metabolome data, providing a reliable tool for the accurate diagnosis of digestive system diseases.

This invention discloses a method for detecting Ag. + The present invention describes a reagent for the detection of C-reactive protein (CRP) and its application therein, wherein the reagent comprises gold nanoparticles. The present invention uses changes in eosin fluorescence intensity as the detection signal and silver halide as the medium, significantly increasing the detection rate of the same concentration of Ag through the co-precipitation effect of AuNPs. + The amount of eosin induced to adsorb, resulting in Ag + The detection limit was increased by 955 times; eosin, AuNPs, silver halides and aptamers (containing Ag) were also improved. + Induced C-C mismatched base pairs can be used for C-reactive protein detection, and can be used to detect the full range of C-reactive protein levels in blood. It also has the potential to be further applied to the detection of other low-concentration disease biomarkers in blood.

The application provides an electric field-induced controllable molecular assembly biosensor, a preparation method and application thereof. The biosensor of the application comprises probe molecules which are orderly and orientally distributed on an interface. The biosensor of the application can stably work in a liquid phase environment; and specific interaction between the probe molecules and target substances provides an effective method for sensitive identification of disease biomarkers and environmental hazardous substances. The application realizes high sensitivity, rapid response and reliable signal analysis of biomarkers by applying an external electric field to directionally induce semiconductor materials and probe molecules to assemble a composite semiconductor layer containing the probe molecules.

This invention belongs to the field of analytical chemistry and biomedical detection, and discloses a method for detecting nucleotides in biological samples based on liquid chromatography-mass spectrometry (LC-MS). The method includes: pretreatment of the biological sample by homogenization with a weakly basic ammonium acetate buffer, protein precipitation with organic solvent, vacuum concentration, and reconstitution; separation using an alkali-resistant C18 column and a weakly basic mobile phase with gradient elution; and detection by multiple reaction monitoring (MRM) in negative ion mode using an electrospray ionization source. This invention can simultaneously detect more than 40 target substances, covering bases, nucleosides, deoxynucleosides, and their phosphorylated forms and modified metabolites, with a limit of quantitation at the ng / pg / mL level. It exhibits strong resistance to matrix interference and excellent chromatographic separation. This method is rapid, highly sensitive, and stable, suitable for high-throughput and precise detection of nucleotides in biological samples, providing a powerful tool for disease biomarker screening and related basic research.

Embodiments relate to borophene-based biosensing platforms for highly sensitive, target-specific biosensing. These embodiments include borophene nanosheets functionalized with biomolecules such as antibodies and oligonucleotides. Such functionalized borophene nanosheets can be integrated into diagnostic devices designed for the targeted detection of disease biomarkers.